RP 01

Drug Profile

RP 01

Alternative Names: RP-01

Latest Information Update: 10 Oct 2014

Price : $50

At a glance

  • Originator Resistentia Pharmaceuticals
  • Class Antiallergics; Antiasthmatics
  • Mechanism of Action Immunoglobulin E inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Allergic asthma; Allergic rhinitis; Peanut hypersensitivity

Most Recent Events

  • 09 Oct 2014 Discontinued - Phase-I for Allergic rhinitis in Sweden (Parenteral)
  • 09 Oct 2014 Discontinued - Phase-I for Peanut hypersensitivity in Sweden (Parenteral)
  • 09 Oct 2014 Discontinued - Phase-II for Allergic asthma in New Zealand (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top